Review Article

Maintenance of Synaptic Stability Requires Calcium-Independent Phospholipase A₂ Activity

Julie Allyson,¹ Xiaoning Bi,² Michel Baudry,² and Guy Massicotte¹

¹ Département de Chimie-Biologie, Université du Québec à Trois-Rivières, 3351 Boulevard des Forges, QC, Canada G9A 5H7
² Graduate College of Biomedical Sciences, Western University of Health Sciences, Pomona, CA 91766-1854, USA

Correspondence should be addressed to Guy Massicotte, guy.massicotte@uqtr.ca

Received 7 October 2011; Revised 3 February 2012; Accepted 7 February 2012

Academic Editor: Lucas Pozzo-Miller

Copyright © 2012 Julie Allyson et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Phospholipases A₂ (PLA₂s) represent one of the largest groups of lipid-modifying enzymes. Over the years, significant advances have been made in understanding their potential physiological and pathological functions. Depending on their calcium requirement for activation, PLA₂s are classified into calcium dependent and independent. This paper mainly focuses on brain calcium-independent PLA₂ (iPLA₂) and on the mechanisms by which they influence neuronal function and regulate synaptic plasticity. Particular attention will be given to the iPLA₂γ isoform and its role in the regulation of synaptic glutamate receptors. In particular, the paper discusses the possibility that brain iPLA₂γ deficiencies could destabilise normal synaptic operation and might contribute to the aetiology of some brain disorders. In this line, the paper presents new data indicating that iPLA₂ γ deficiencies accentuate AMPA receptor destabilization and tau phosphorylation, which suggests that this iPLA₂ isoform should be considered as a potential target for the treatment of Tau-related disorders.

1. Introduction

The nervous system is formed by integrated neuronal circuits which all require constant adaptation for stabilizing their activities in the face of perturbations that alter, for instance, neuronal excitability. Phenomena that conform to this definition include the activity-dependent regulation of intrinsic neuronal firing properties [1, 2], pre- and postsynaptic forms of excitatory synaptic plasticity, such as synaptic scaling, that adjust all of a neuron’s excitatory synapses up or down in the right direction to stabilize firing [3, 4]; the balancing of excitation and inhibition within neuronal networks [5, 6]; compensatory changes in synapse number [7]; apposition of presynaptic and postsynaptic elements [4] and metaplastic mechanisms that adjust long-term changes in synaptic operation [8, 9]. In general, it is believed that the final refinements of neuronal circuits rely on the stabilization of functionally appropriate connections and the elimination of inappropriate ones.

While the molecular mechanisms of synapse formation have been extensively studied, very little is known about the molecular mechanisms that are responsible for stabilization of synaptic connections. Over the recent years, however, it has been proposed that the level of AMPA subtype of glutamate receptors found at neuronal connections might be a crucial component controlling both stabilization of presynaptic inputs and postsynaptic spine morphogenesis (see [10]). In the present paper, we will focus on the possibility that a specific PLA₂ isoform can interact with AMPA receptor properties to contribute to synaptic stabilization. We will, in this line, present some new information indicating that iPLA₂γ deficiency might undermine the normal stabilizing mechanisms underlying memory formation in the hippocampus and contribute to Alzheimer’s disease pathology.

2. iPLA₂ Isoforms, Long-Term Potentiation, and Memory Stabilization

Phospholipases A₂ (PLA₂s) constitute a large and diverse group of enzymes with broad biological functions, ranging from membrane synthesis and turnover to the generation of
signaling molecules. So far, more than 20 isoforms of PLA2 with diverse characteristics, including calcium requirement and subcellular localization, have been identified. Based on nucleotide sequences as well as other properties, PLA2s have been categorized into 15 groups (I–XV) [11, 12]. Several types of released small PLA2s (∼14 kDa) require millimolar amounts of calcium for optimal activation. These enzymes have historically been called the secreted forms of PLA2 (or sPLA2). The remaining groups are larger proteins, localized in intracellular compartments, and are either calcium dependent or independent.

The first intracellular PLA2 to be cloned was a protein of 85-kDa, classified as group IV PLA2 [13, 14]. This enzyme, now designated as cytosolic PLA2α (cPLA2α), is under the influence of extracellular signals likely to induce calcium mobilization and phosphorylation reactions [13]. Another group of PLA2 (group VI), which does not require calcium variations for activity, has been cloned [15–17]. This PLA2 isoform has been designated as calcium-independent PLA2 (iPLA2) (Table 1) [14, 18], and according to numerous lines of biochemical evidence may account for most PLA2 activity under resting conditions. Whereas cPLA2 and sPLA2 are commonly believed to be preferentially involved in AA release, emerging evidence indicates that iPLA2 activity can contribute to docosahexaenoic acid (DHA) release from brain phospholipids. Pharmacologically, iPLA2 activity is markedly reduced by bromoenol lactone (BEL), a suicide analog of the catalytic triad of PLA2 that is not an effective inhibitor of sPLA2 or cPLA2 at comparable concentrations [15–17]. The precise pattern of expression of both group VI A iPLA2 (iPLA2γ) and group VI B iPLA2 (iPLA2β) in different stages of human embryonic and early fetal development, iPLA2s show a dynamic expression pattern both in terms of the location of expression and the differentiation state of expressing cells. In brief, iPLA2s are expressed in forebrain and midbrain before it is detectable in hindbrain. Throughout the developing brain, iPLA2s are mainly expressed in proliferative zones, suggesting that these enzymes are important for early neuronal development [38]. The precise pattern of expression of both group VI A iPLA2 (iPLA2β) and group VI B iPLA2 (iPLA2γ) enzymes still unclear, and one important priority for future studies will be the precise identification of iPLA2 isoforms responsible for brain development and stabilization.

Group VI A iPLA2β, the most extensively studied iPLA2 isoform, has been implicated in various cellular events, such as phospholipid remodeling [18, 39], eicosanoid formation [40], cell growth [41, 42], apoptosis [43], and

| Group  | Source          | Molecular mass (kDa) | Feature                        | Alternate names |
|--------|-----------------|----------------------|--------------------------------|-----------------|
| VIA-1  | Human/Murine    | 84–85                | 8 ankyrin repeats               | iPLA2α          |
| VIA-2  | Human/Murine    | 88–90                | 7 ankyrin repeats               | iPLA2β          |
| VIB    | Human/Murine    | 88–91                | Membrane-bound                  | iPLA2γ          |
| VIC    | Human/Murine    | 146                  | Integral membrane protein       | iPLA2δ          |
| VID    | Human           | 53                   | Acylglycerol transacylase, triglycerol lipase | iPLA2ε          |
| VIE    | Human           | 57                   | Acylglycerol transacylase, triglycerol lipase | iPLA2ξ          |
| VIF    | Human           | 28                   | Acylglycerol transacylase, triglycerol lipase | PLA2η           |

Table 1: Calcium-independent group VI phospholipase A2 (iPLA2).
activation of store-operated channels and capacitative calcium influx [44]. Disruption of the iPLA2β gene causes impaired sperm motility [45], mitigated insulin secretion [46, 47], and neuronal disorders with iron dyshomeostasis [48]. Group VIβ iPLA2γ is a membrane-bound iPLA2 enzyme with unique features, such as the utilization of distinct translation initiation sites producing different sizes of enzymes with distinct subcellular localizations [36, 49–53] and phospholipid selectivity in terms of sn-1/sn-2 positional specificity, which differs among substrates [54]. iPLA2γ has a mitochondrial localization signal in the N-terminal region and a peroxisomal localization signal near the C-terminus, and the 88-kDa full-length and 63-kDa translation products of iPLA2γ are preferentially distributed in mito-
chondria and peroxisomes, respectively [49–51]. In brain, iPLA2 constitutes the predominant phospholipase activity under resting conditions [55, 56]. Reverse transcription-polymerase chain reaction experiments have revealed that rat brain constitutively expresses mRNAs for at least 3 calcium-independent PLA2 isoforms, iPLA2β, iPLA2γ and cPLA2γ [16, 57, 58]. These isoforms are characterized by different sensitivity to PLA2 inhibitors, including different enantiomers of an inhibitor; Jenkins et al. [59] established that the (S)-enantiomer of BEL selectively reduces iPLA2β activity, while its (R)-enantiomer blocks the iPLA2γ isoform more efficiently.

Although little is known about iPLA2 functions in neurons, a growing body of evidence suggests their involvement in hippocampal long-term potentiation (LTP) of excitatory synaptic transmission [55, 60]. Hippocampal LTP, first described by Bliss and Lomo in 1973, is commonly regarded as a functional model of synaptic adaptation (i.e., plasticity) that likely participates in certain forms of learning and memory [61–63]. PLA2 activities are increased in membranes prepared from the dentate gyrus after LTP induction in anaesthetised rats [64]; it has been proposed that PLA2 could be involved in hippocampal LTP expression by elevating the production of arachidonic acid (AA) that could retrogradely increase transmitter release at glutamatergic synapses [65, 66]. The hypothesis that facilitation of transmitter release by PLA2s occurs during LTP is reinforced by the fact that iPLA2 activity plays an important role in membrane fusion processes required for exocytosis [21, 67].

The notion that iPLA2 activity may facilitate LTP expression by increasing glutamate release is contradicted, however, by a number of reports demonstrating that synaptic potentiation, at least in area CA1 of hippocampus, is not dependent on changes in transmitter release, but rather is mediated by upregulation of postsynaptic responses mediated by alpha-amino-3-hydroxy-5-methyl-4-
isoxazole-propionic acid (AMPA) receptors at glutamatergic synapses [68, 69]. Several alterations have been reported at postsynaptic sites during LTP, including faster kinetics of receptor ion channels [70, 71], redistribution of existing receptors within the postsynaptic density [72], and insertion of new receptors at synapses [73, 74]. Consistent with these observations, we recently demonstrated that pretreatment of hippocampal slices with the iPLA2 inhibitor BEL completely abolishes AMPA receptor translocation in synaptic membranes and expression of CA1 hippocampal LTP [75]. Interestingly, both LTP and AMPA receptor translocation display enantio-selective impairment by the iPLA2γ blocker (R)-BEL but not by the iPLA2β inhibitor (S)-BEL, suggesting that iPLA2γ represents the crucial isoform governing hippocampal synaptic stability. iPLA2γ mRNAs and proteins are enriched with the endoplasmic reticulum (ER)-Golgi apparatus in several cell types [57], where they may be essential for diverse intracellular trafficking pathways, such as retrograde movement from the Golgi complex to the ER, transport of material from the trans-Golgi network to the plasma membrane, or recycling of membranes and receptors through endocytic pathways [21]. In particular, Péchoux et al. [76] reported that iPLA2 inhibition slowed down the transport of caseins from the ER to the Golgi apparatus and from the trans-Golgi network to the plasma membrane, indicating that iPLA2 could participate in membrane trafficking events leading to the secretion of milk proteins. Since AMPA receptors trafficking from the ER-Golgi complex to postsynaptic membranes is critically involved in LTP [77], the iPLA2γ isoform may be well suited to facilitate AMPA receptor translocation from intracellular pools to synaptic membranes during LTP.

Animal experiments have revealed that PLA2 inhibition resulted in synaptic plasticity impairment and decreased performance in memory tasks. For instance, intracerebral injection of wide-spectrum PLA2 inhibitors into chick intermediate medial hyperstriatum ventrale curbs the learning of a passive avoidance task [78], while intraperitoneal injection in rats impedes spatial learning in the Morris water maze [79]. Likewise, intracerebroventricular or intrahippocampal injection of specific iPLA2 inhibitors impairs spatial working memory in rodents [80]. In addition, acquisition of 1-trial step-down inhibitory avoidance in rats was shown to be correlated with increased iPLA2 activity in hippocampus, while bilateral injection of iPLA2 inhibitors in region CA1 of the dorsal hippocampus prior to training hindered both short-term and long-term memory [81]. In a modified protocol developed to test memory retrieval, the same group recently showed that injection of the dual cPLA2 and iPLA2 inhibitor palmitoyl trifluoromethylketone in region CA1 of the rat dorsal hippocampus before performance testing impaired trained behaviour in the step-down inhibitory avoidance task [82]. Importantly, memory retrieval was re-established after recovery of PLA2 activity, indicating that these PLA2s are indeed necessary for memory stabilization. Hence, intact iPLA2 activity seems to be critical for proper memory acquisition as well as retrieval. However, the identity of iPLA2 isoforms involved in memory acquisition and retrieval remains to be determined.

3. iPLA2 and Neuronal Cell Death Mechanisms

Recently, evidence from studies with nonneuronal cells has suggested that iPLA2 enzymes may have diverse effects on cell death. First, constitutive iPLA2 activity may contribute to cell death since iPLA2β overexpression amplifies thapsigargin-induced apoptosis in INS-1 insulinoma cells [83] and accelerates U937 cell death after long-term exposure to
hydrogen peroxide [84]. iPLA\(_2\) has been shown to play a pivotal role in oxidative damage of astrocytes [85], and its blockade by BEL dampens oligomeric amyloid-\(\beta\) (\(\beta\)1-42-) induced mitochondrial membrane potential loss and reactive oxygen species production in these cells [86]. Moreover, iPLA\(_2\) inhibition reduces the size of infarcts produced by global ischemia [87]. On the other hand, iPLA\(_2\) activity has also been shown to protect against cell death, as inhibition of iPLA\(_2\) accentuates oxidant-induced cell death in renal proximal tubule cells and astrocytes [88, 89]. Likewise, iPLA\(_2\) activity may also have deleterious or beneficial effects on neurons. For instance, acute inhibition of iPLA\(_2\) activity by racemic BEL has been found to be neuroprotective in organotypic hippocampal slices exposed to oxygen-glucose deprivation [90]. In contrast, immature cultures of primary cortical neurons exposed for several days to BEL showed decreased cellular viability and neuritic growth [91, 92]. Moreover, iPLA\(_2\)\(\beta\) knockout mice exhibit abnormal motor behaviors possibly related to the appearance of vacuoles and ubiquitin-positive axonal swelling (spheroids) in many brain regions [93, 94], suggesting that iPLA\(_2\)\(\beta\) dysfunction leads to axonal dystrophy.

While the reported impact of iPLA\(_2\) on cell viability is mostly attributable to iPLA\(_2\)\(\beta\), involvement of the iPLA\(_2\)\(\gamma\) isoform is much less clear. A previous report demonstrated that iPLA\(_2\)\(\gamma\) localized in mitochondria catalyzed AA liberation that mediated mitochondrial permeability transition, a key control point for apoptosis [95]. On the other hand, iPLA\(_2\)\(\gamma\) expression may exert cytoprotective effects during complement-mediated glomerular epithelial cell injury [96]. In addition, recent findings from our laboratory have revealed that constitutive iPLA\(_2\)\(\gamma\) activity might represent an important neuroprotective system capable of limiting brain excitotoxic damage. In particular, we showed that iPLA\(_2\)\(\gamma\) inhibition by the enantio-specific inhibitor (R)-BEL makes cultured hippocampal slices more vulnerable to AMPA-mediated excitotoxicity [97]. Overactivation of N-methyl-D-aspartic acid (NMDA) or AMPA receptors results in a massive entry of calcium into cells, leading to the activation of a number of enzymes, including AT\(\gamma\)ases, lipases, proteases, and endonucleases that, in turn, deplete energy stores or damage cell membranes, cytoarchitecture or nuclear components, respectively. Excitotoxicity has been reported to contribute to a variety of neuropathological disorders, including ischemic stroke, epilepsy, amyotrophic lateral sclerosis, and Alzheimer’s disease (AD) [98, 99].

Interestingly, iPLA\(_2\)\(\gamma\) inhibition-induced enhancement of AMPA-mediated toxicity is associated with selective phosphorylation and upregulation of the AMPA receptor GluR1 but not GluR2 subunits in synaptic membrane fractions [97, 98, 100]. In hippocampus, AMPA receptors generally form heterodimers containing 2 copies of each of the GluR1 and GluR2 subunits. It is now well-recognized that the presence of GluR2 subunits render AMPA receptors impermeable to calcium. Consequently, its presence or absence plays a critical role in cellular calcium homeostasis and in determining susceptibility to excitotoxicity [101, 102]. Hence, iPLA\(_2\)\(\gamma\) inhibition, by promoting surface expression of GluR1 over GluR2 subunits (which is reflected by a rise in the GluR1/GluR2 ratio in the membrane fraction), could exacerbate excitotoxic cell death through the increased formation of GluR2-lacking AMPA receptors that would allow adverse Ca\(^{2+}\) influx upon prolonged AMPA receptor activation. Consistent with this possibility, the greater cell death observed following iPLA\(_2\)\(\gamma\) inhibition is prevented by GluR1/3-specific AMPA receptor antagonists [97]. How inhibition of iPLA\(_2\)\(\gamma\) influences the expression of AMPA receptor subtypes in synaptic membranes remains an open question. As mentioned earlier, this may be the result of an effect of the lipase on protein transport through intracellular secretory pathways [76]. There are other circumstances in which GluR1 subunits are selectively upregulated in hippocampal neurons, such as after neuronal activity inhibition elicited by prolonged blockade of AMPA receptors [103] or by tumor necrosis factor-alpha receptor activation [104]. In the latter case, it has been proposed that upregulation of GluR1 homomeric receptors could be produced by a reserve pool of non-GluR2-containing AMPA receptors located near the membrane. Independently of the exact mechanism, these observations raise the possibility that constitutive iPLA\(_2\)\(\gamma\) activity may be a crucial mechanism to maintain synaptic stability and constitute a molecular device to prevent neuronal dysfunctions.

4. iPLA\(_2\) Dysfunction and Neurodegenerative Disorders

As previously described, cPLA\(_2\) and sPLA\(_2\) are commonly believed to be preferentially involved in AA release; emerging evidence indicates that iPLA\(_2\) activity can contribute to docosahexaenoic acid (DHA) release from brain phospholipids [105]. The first suggestion that brain iPLA\(_2\) activity may be crucial for DHA release came from a study by Strokin et al. [106] who showed that racemic BEL inhibited DHA release from astrocytes. Later, using siRNA silencing procedures, the same group demonstrated that DHA release from astrocytic phospholipids was mainly dependent on iPLA\(_2\) activity [107]. DHA is one of the most abundant omega-3 polyunsaturated fatty acids (PUFA) present in phospholipids of mammalian brain [108], where it is recognized to be important for the maintenance of neural membranes and brain function integrity [109]. Deficiency in dietary intake of DHA has been associated with lower performance in learning tasks in rodents [110–112]. On the other hand, DHA dietary supplementation was shown to decrease the risk of developing AD [113–115] and to exert neuroprotective actions in a mouse model presenting numerous aspects of Parkinson’s disease [116], while high-fat consumption combined with low omega-3 PUFA intake promoted AD-like neuropathology [117]. Both iPLA\(_2\) activity and DHA levels have been reported to be decreased in the plasma of AD patients [118, 119]. Lower iPLA\(_2\) activity has also been reported in AD brains [120, 121]. Whether or not decreased iPLA\(_2\)\(\gamma\) activity is a factor contributing to AD pathology remains to be established. Numerous neurobiological studies have demonstrated that DHA may be acting in different cellular pathways to counteract several
molecular manifestations of AD. There are, for instance, strong indications that DHA release in the brain may diminish oxidative stress [122, 123] and glutamate-induced toxicity [124]. In this line, DHA-induced reduction of excitotoxic damage in hippocampus might be dependent on internalization of AMPA receptors [125]. The potential ability of DHA to reduce caspase activation [114, 115], Aβ peptide accumulation, and Tau hyperphosphorylation [126, 127] also strongly supports the notion that DHA deficiency, as a result of iPLA2 deficiency, could represent a precursor event that could initiate the cellular manifestations of AD pathology.

Normally, Tau predominantly localizes to neuronal axons where it modulates the stability and assembly of microtubules [128, 129]. In so doing, Tau generates a partially stable, but still dynamic, state in microtubules that is important for axonal growth and effective axonal transport [130]. In addition to binding microtubules, some but not all studies provide evidence that Tau can interact, either directly or indirectly, with actin and affect actin polymerization as well as the interaction of actin filaments with microtubules [131, 132]. Furthermore, Tau appears to interact with the plasma membrane and with several proteins involved in signal transduction [133–141]. From a pathological perspective, Tau dysfunction resulting from biochemical defects (i.e., aberrant phosphorylation, truncation, and glycosylation) has been proposed to be an important factor contributing to the initiation and development of several neuropathological conditions such as AD [142–147]. As discussed above, lower iPLA2 activity has been observed in AD brains and considering our hypothesis that iPLA2γ is an important factor controlling AMPA-mediated toxicity in the hippocampus, we anticipated that defect in iPLA2γ activity can contribute to enhance Tau phosphorylation. Here, we are presenting the first experimental evidence that Tau become hyperphosphorylated after selective inhibition of iPLA2γ. We first examined Tau phosphorylation levels at Ser199 residue following treatment of hippocampal slices with R-BEL and S-BEL, which preferentially block iPLA2γ or iPLA2β, respectively (see chemical structures; Figure 1(a)). In initial experiments, we observed that hippocampal tissues were strongly and consistently stained with an antibody recognizing the phosphorylated Ser199 epitope of a Tau isoform of 62 kDa (Figure 1(b), top panels). As shown in Figure 1, staining for this hyperphosphorylated Tau isoform increased following iPLA2γ inhibition by R-BEL. When the results were normalized with staining levels of Tau-5 (an antibody that recognizes Tau independent phosphorylation), it appears that R-BEL elevated levels of phosphorylated Tau at all concentrations tested, with a maximal increase of 120 ± 10% over control values in slices preincubated for 3 hr. However, the same analysis showed that phosphorylation of Tau at Ser199 was not altered by exposure to the iPLA2β inhibitor S-BEL. It is noteworthy that levels of Tau-5 immunoreactivity in the hippocampal slices were not significantly changed by treatments with either R- or S-BEL, indicating that iPLA2γ inhibition-induced increases in Ser199 phosphorylation do not depend on Tau synthesis and/or degradation. De-Paula and collaborators recently showed that injection of the dual cPLA2 and iPLA2 inhibitor methyl arachidonyl fluorophosphonate (MAFP) induced Tau phosphorylation at Ser214 [148]. In contrast to our results, however, they reported that Tau hyperphosphorylation was associated with a reduction in levels of total Tau [149], suggesting that inhibition of both cPLA2 and iPLA2 might influence several biochemical aspects of Tau proteins. Accordingly, recent experimental results have provided evidence that cPLA2 and iPLA2 activities can play divergent roles during spinal cord injuries [150]. We recently tested the effect of R-BEL-mediated iPLA2γ inhibition on Tau subcellular localization in CA1 pyramidal cells. Using organotypic hippocampal slice cultured from transgenic mice expressing human Tau, we observed that treatment with the specific iPLA2γ inhibitor (R)-BEL for up to 12 hr resulted in increases in Tau phosphorylation at the Thr231 site. High-resolution imaging showed that hyperphosphorylated Tau was primarily localized in the cell bodies and dendrites of hippocampal pyramidal neurons (see Figure 2).

One of the central hypotheses for AD pathogenesis is that the production of cytotoxic Aβ peptides impairs neuronal activity and leads to a decline in memory and cognition [151]. Some PLA2 enzymes may exacerbate Aβ cytotoxicity, as Aβ peptides stimulate cPLA2α activity in neuronal cultures [86] and primary cortical astrocytes [152]; in addition, Aβ-induced learning and memory deficits in a transgenic mouse model of AD are prevented by genetic ablation of cPLA2α activity in brain [152]. On the other hand, it has been well established that iPLA2 activity is essential for maintaining membrane phospholipid integrity by reducing peroxidative damage, especially that originating in mitochondria. In this regard, iPLA2 expression prevents the loss of mitochondrial membrane potential and attenuates the release of cytochrome c as well as of other apoptotic proteins, and ultimately reduces apoptosis in INS-1 cells exposed to staurosporine [153]. Furthermore, Kinsey et al. [95, 154] reported that a major component of PLA2 activity in mitochondria of rabbit renal proximal tubular cells is provided by iPLA2γ and is of critical importance for the prevention of basal lipid peroxidation and maintenance of mitochondrial viability. Based on recent studies, it has been proposed that Aβ-induced neurotoxicity might derive from mitochondrial defects. Indeed, in vitro experiments have shown that Aβ peptides can be internalized by cells, imported into mitochondria and ultimately elicit mitochondrial dysfunctions [155]. Given its localization, it is thus tempting to propose that iPLA2γ might represent an important cellular component that prevents mitochondrial dysfunctions. Experiments are required to determine whether iPLA2γ overexpression activity might exert protective effects against Aβ peptide-induced mitochondrial dysfunctions.

From a pathological perspective, it has been demonstrated that iPLA2 activity is upregulated in the hippocampus of patients suffering from schizophrenia [156]. The precise implication of this iPLA2 dysfunction in the development of schizophrenia-related symptoms remains unknown. However, the results presented above would predict that upregulation of iPLA2γ activity could eventually lead to reduction in GluR1-containing receptors. Interestingly, GluR1
Figure 1: Hippocampal Tau phosphorylation at Ser199 residue is accentuated by R-BEL. Hippocampal slices (350 μm) were pre-incubated at 32°C for 3 h with DMSO alone (control) or with increasing concentrations of the iPLA2γ inhibitor R-BEL or the iPLA2β inhibitor S-BEL (chemical structures of both compounds are presented in (a)). (b) Phosphorylation and Tau protein levels were determined by Western blotting of cell extracts (40 μg of proteins) obtained from acute hippocampal slices. Phosphorylated Tau levels, expressed relative to total Tau (i.e., Tau-5; AbCam, Cambridge, MA, USA. Dilution 1:500), were measured using antibodies raised against Tau phosphorylated at Ser199 (AbCam, Cambridge, MA, USA. Dilution 1:1,000). The data were expressed as percentage of control values and are means ± SEM of 3 measurements per cell extract obtained from 7 different rats. Statistical analysis was performed by one-way ANOVA followed by Neuman-Keuls’ post hoc test. *P < 0.05, **P < 0.01, ***P < 0.001, drug-treated versus control.

downregulation has been reported to evoke striatal hyperdopaminergic activity [157], a well-established biological defect involved in schizophrenia-related symptoms. The potential relationship between iPLA2γ and the dopaminergic system is reinforced by the fact that iPLA2γ inhibition or knockdown in rat striatum, motor cortex and thalamus results in the apparition of Parkinson-related manifestations [158], which are also known to depend on dopamine dysfunction. Of course, future experiments will be required to establish the potential role of iPLA2γ enzymes in stabilizing dopamine-mediated responses.

5. Conclusion

Here, we have summarized growing evidence linking iPLA2γ activity to the stabilization of synaptic AMPA receptor properties in hippocampal neurons. First, it appears evident that without appropriate levels of iPLA2γ activity in area CA1 of hippocampal slices synaptic stabilization of AMPA receptors, which is required for the expression of long-term changes in synaptic strength (i.e., LTP), is compromised. As mentioned previously, iPLA2γ mRNAs and proteins are enriched with the endoplasmic reticulum (ER)-Golgi apparatus in several cell type, where they will be essential for diverse intracellular trafficking pathways, such as retrograde movement from the Golgi complex to the ER, transport of material from the trans-Golgi network to the plasma membrane, or recycling of membranes and receptors through endocytic pathways [21]. Since AMPA receptors trafficking from the ER-Golgi complex to postsynaptic membranes is critically involved in LTP [77], the iPLA2γ isoform may be well suited to facilitate AMPA receptor translocation from intracellular pools to synaptic membranes during LTP. However, given their biochemical properties and
Figure 2: Inhibition of iPLA$_2$Y induces Tau phosphorylation in area CA1 of hippocampus. Cultured hippocampal slices from P301L Tau transgenic mice were treated with the iPLA$_2$Y inhibitor (R)-BEL. Slices were then processed for confocal immunofluorescence microscopy with an antibody recognizing Tau phosphorylation at Threonine 231 epitopes (AT231, in green) (AbCam, Cambridge, MA, USA. Dilution 1:750). When compared to controls (upper panel), immunostaining revealed increased phosphorylation in the CA1 region of cultured hippocampal slices incubated with 3 μM (R)-BEL for a period of 12 h (lower panel). DAPI (in blue) was included in the mounting medium to label nuclei. This observation was qualitatively reproduced in hippocampal slices obtained in 3 different cultures. Scale bar = 25 μm.

Figure 3: A putative model illustrating the potential implication of iPLA$_2$Y in Alzheimer’s disease. In this simplified model, iPLA$_2$Y dysfunction leads to excessive delivery of GluR1-containing receptors to neuronal membranes. These receptors are more likely to be calcium-permeable and therefore to stimulate calcium influx and, eventually, Tau phosphorylation by calcium-dependent protein kinases such as Cdk5 and GSK-3β. Localization, future experiments will be required to determine how the effects of iPLA$_2$Y on LTP might derive from alterations of other cellular processes controlling synaptic stability such as regulation of arachidonic acid release, membrane fusion events, receptor trafficking pathways, and protein kinase activities. Besides, we also documented that iPLA$_2$Y deficiency can destabilize synaptic GluR1 subunits of AMPA receptors in hippocampal membranes and accentuate glutamate-induced toxicity. In this line, iPLA$_2$Y-null mice have been generated [159, 160] and were found to exhibit phenotypic abnormalities that include altered mitochondrial morphology, function, and lipid composition associated with hippocampal degeneration. Interestingly, we provided here preliminary evidence showing that iPLA$_2$Y activity appears to be important for stabilizing Tau phosphorylation in hippocampal pyramidal neurons, suggesting that downregulation of iPLA$_2$Y activity may contribute to the development of tauopathies in AD [161]. A putative biochemical model that could account for the potential influence of iPLA$_2$Y on Tau pathology is presented in Figure 3. Indeed, considering the growing evidence relating the importance of iPLA$_2$Y in physiological and pathological conditions, targeting iPLA$_2$Y activity may represent a potentially new
therapeutic strategy to address several neurological disorders characterized with destabilisation of synaptic properties.

References

[1] E. Marder and A. A. Prinz, “Current compensation in neuronal homeostasis,” Neuron, vol. 37, no. 1, pp. 2–4, 2003.
[2] W. Zhang and D. J. Linden, “The other side of the engram: experience-driven changes in neuronal intrinsic excitability,” Nature Reviews Neuroscience, vol. 4, no. 11, pp. 885–900, 2003.
[3] R. C. Malenka and R. A. Nicoll, “Long-term potentiation—a decade of progress?” Science, vol. 285, no. 5435, pp. 1870–1874, 1999.
[4] G. G. Turrigiano and S. B. Nelson, “Homeostatic plasticity in the developing nervous system,” Nature Reviews Neuroscience, vol. 5, no. 2, pp. 97–107, 2004.
[5] C. Gonzalez-Islas and P. Wenner, “Spontaneous network activity in the embryonic spinal cord regulates AMPAergic and GABAergic synaptic strength,” Neuron, vol. 49, no. 4, pp. 563–575, 2006.
[6] A. Maffei, S. B. Nelson, and G. G. Turrigiano, “Selective reconfiguration of layer 4 visual cortical circuitry by visual deprivation,” Nature Neuroscience, vol. 7, no. 12, pp. 1353–1359, 2004.
[7] C. J. Wierenga, M. F. Walsh, and G. G. Turrigiano, “Temporal regulation of the expression locus of homeostatic plasticity,” Journal of Neurophysiology, vol. 96, no. 4, pp. 2127–2133, 2006.
[8] W. C. Abraham and M. F. Bear, “Metaplasticity: the plasticity of synaptic plasticity,” Trends in Neurosciences, vol. 19, no. 4, pp. 126–130, 1996.
[9] E. L. Bienenstock, L. N. Cooper, and P. W. Munro, “Theory for the development of neuron selectivity: orientation specificity and binocular interaction in visual cortex,” Journal of Neuroscience, vol. 2, no. 1, pp. 32–48, 1982.
[10] B. Ripley, S. Otto, K. Tiglio, M. E. Williams, and A. Ghosh, “Regulation of synaptic stability by AMPA receptor reverse signaling,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 1, pp. 367–372, 2011.
[11] J. E. Burke and E. A. Dennis, “Phospholipase A2 biochemistry,” Cardiovascular Drugs and Therapy, vol. 23, no. 1, pp. 49–59, 2009.
[12] J. E. Burke and E. A. Dennis, “Phospholipase A2 structure/function, mechanism, and signaling,” Journal of Lipid Research, vol. 50, pp. S237–242, 2009.
[13] C. C. Leslie, “Properties and regulation of cytosolic phospholipase A2,” Journal of Biological Chemistry, vol. 272, no. 27, pp. 16709–16712, 1997.
[14] E. A. Dennis, “The growing phospholipase A2 superfamily of signal transduction enzymes,” Trends in Biochemical Sciences, vol. 22, no. 1, pp. 1–2, 1997.
[15] M. A. Balboa, J. Balsinde, S. S. Jones, and E. A. Dennis, “Identity between the CA2+-independent phospholipase A2 enzymes from P388D1 macrophages and Chinese hamster ovary cells,” Journal of Biological Chemistry, vol. 272, no. 13, pp. 8576–8580, 1997.
[16] J. Tang, R. W. Kriz, N. Wolfman, M. Shaffer, J. Seehra, and S. S. Jones, “A novel cytosolic calcium-independent phospholipase A2 contains eight ankyrin motifs,” Journal of Biological Chemistry, vol. 272, no. 13, pp. 8567–8575, 1997.
[17] Z. Ma, S. Ramanadham, K. Kempe, X. S. Chi, J. Ladenson, and J. Turk, “Pancreatic islets express a CA2+-independent phospholipase A2 enzyme that contains a repeated structural motif homologous to the integral membrane protein binding domain of ankyrin,” Journal of Biological Chemistry, vol. 272, no. 17, pp. 11118–11127, 1997.
[18] J. Balsinde and E. A. Dennis, “Function and inhibition of intracellular calcium-independent phospholipase A2,” Journal of Biological Chemistry, vol. 272, no. 26, pp. 16069–16072, 1997.
[19] I. Kudo and M. Murakami, “Phospholipase A2 enzymes,” Prostaglandins and Other Lipid Mediators, vol. 68-69, pp. 3–58, 2002.
[20] N. G. Bazan, G. Allan, and E. B. Rodriguez De Turco, “Role of phospholipase A2 and membrane-derived lipid second messengers in membrane function and transcriptional activation of genes: implications in cerebral ischemia and neuronal excitability,” Progress in Brain Research, vol. 96, pp. 247–257, 1993.
[21] W. J. Brown, K. Chambers, and A. Doody, “Phospholipase A2 (PLA2) enzymes in membrane trafficking: mediators of membrane shape and function,” Traffic, vol. 4, no. 4, pp. 214–221, 2003.
[22] A. A. Farooqui and L. A. Horrocks, “Brain phospholipases A2; a perspective on the history,” Prostaglandins Leukotrienes and Essential Fatty Acids, vol. 71, no. 3, pp. 161–169, 2004.
[23] A. A. Farooqui, W. Y. Ong, and L. A. Horrocks, “Biochemical aspects of neurodegeneration in human brain: involvement of neural membrane phospholipids and phospholipases A2,” Neurochemical Research, vol. 29, no. 11, pp. 1961–1977, 2004.
[24] M. Kolko, J. U. Prause, N. G. Bazan, and S. Heggaard, “Human secretory phospholipase A2 group IB in normal eyes and in eye diseases,” Acta Ophthalmologica Scandinavica, vol. 85, no. 3, pp. 317–323, 2007.
[25] C. C. Leslie, “Regulation of arachidonic acid availability for eicosanoid production,” Biochemistry and Cell Biology, vol. 82, no. 1, pp. 1–17, 2004.
[26] J. W. Phillips and M. H. O’Regan, “A potentially critical role of phospholipases in central nervous system ischemic, traumatic, and neurodegenerative disorders,” Brain Research Reviews, vol. 44, no. 1, pp. 13–47, 2004.
[27] J. Balsinde and M. A. Balboa, “Cellular regulation and proposed biological functions of group VIA calcium-independent phospholipase A2 in activated cells,” Cellular Signalling, vol. 17, no. 9, pp. 1052–1062, 2005.
[28] S. B. Hooks and B. S. Cummings, “Role of CA2+-independent phospholipase A2 in cell growth and signaling,” Biochemical Pharmacology, vol. 76, no. 9, pp. 1059–1067, 2008.
[29] G. Y. Sun, J. Xu, M. D. Jensen et al., “Phospholipase A2 in astrocytes: responses to oxidative stress, inflammation, and G protein-coupled receptor agonists,” Molecular Neurobiology, vol. 31, no. 1–3, pp. 27–41, 2005.
[30] G. Y. Sun, J. Xu, M. D. Jensen, and A. Simony, “Phospholipase A2 in the central nervous system: implications for neurodegenerative diseases,” Journal of Lipid Research, vol. 45, no. 2, pp. 205–213, 2004.
[31] J. V. Bonventre, Z. Huang, M. R. Taheri et al., “Reduced fertility and postischaemic brain injury in mice deficient in cytosolic phospholipase A2,” Nature, vol. 390, no. 6660, pp. 622–625, 1997.
[32] H. Uozumi, K. Kume, T. Nagase et al., “Role of cytosolic phospholipase A2 in allergic response and parturition,” Nature, vol. 390, no. 6660, pp. 618–622, 1997.
[33] G. B. Quistad, C. Barlow, C. J. Winrow, S. E. Sparks, and J. E. Casida, "Evidence that mouse brain neuropathy target esterase is a lysophospholipase," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 100, no. 13, pp. 7983–7987, 2003.

[34] C. M. Jenkins, D. J. Mancuso, W. Yan, H. F. Sims, B. Gibson, and R. W. Gross, "Identification, cloning, expression, and purification of three novel human calcium-independent phospholipase A₂ family members possessing triacylglycerol lipase and acylglycerol transacylase activities," *Journal of Biological Chemistry*, vol. 279, no. 47, pp. 48968–48975, 2004.

[35] T. J. Rydel, J. M. Williams, E. Krieger et al., "The crystal structure, mutagenesis, and activity studies reveal that patatin is a lipid acyl hydrolase with a Ser-Asp catalytic dyad," *Biochemistry*, vol. 42, no. 22, pp. 6696–6708, 2003.

[36] D. J. Mancuso, C. M. Jenkins, and R. W. Gross, "The genomic organization, complete mRNA sequence, cloning, and expression of a novel human intracellular membrane-associated calcium- independent phospholipase A₂," *Journal of Biological Chemistry*, vol. 275, no. 14, pp. 9937–9945, 2000.

[37] M. Murakami, Y. Taketomi, Y. Miki, H. Sato, T. Hirabayashi, and K. Yamamoto, "Recent progress in phospholipase A₂ research: from cells to animals to humans," *Progress in Lipid Research*, vol. 50, no. 2, pp. 152–192, 2011.

[38] B. Polster, M. Crosier, S. Lindsay, and S. Hayflick, "Expression of PLA₂G₆ in human fetal development: implications for infantile neuroaxonal dystrophy," *Brain Research Bulletin*, vol. 83, no. 6, pp. 374–379, 2010.

[39] I. Balsinde, M. A. Balboa, and E. A. Dennis, "Antisense inhibition of group VI CA²⁺-independent phospholipase A₂ blocks phospholipid fatty acid remodeling in murine P388D1 macrophages," *Journal of Biological Chemistry*, vol. 272, no. 46, pp. 29317–29321, 1997.

[40] H. K. Tay and A. J. Melendez, "FcyRI-triggered generation of arachidonic acid and eicosanoids requires iPLA₂ but not cPLA₂ in human monocytic cells," *Journal of Biological Chemistry*, vol. 279, no. 21, pp. 22505–22513, 2004.

[41] B. Sun, X. Zhang, C. Yonz, and B. S. Cummings, "Inhibition of calcium-independent phospholipase A₂ activates p38 MAPK signaling pathways during cytostasis in prostate cancer cells," *Biochemical Pharmacology*, vol. 79, no. 12, pp. 1727–1735, 2010.

[42] S. P. Herbert and J. H. Walker, "Group VIA calcium-independent phospholipase A₂ mediates endothelial cell S phase progression," *Journal of Biological Chemistry*, vol. 281, no. 47, pp. 35709–35716, 2006.

[43] G. I. Atsumi, M. Tajima, A. Hadano, Y. Nakatani, M. Murakami, and I. Kudot, "Fas-induced arachidonic acid release is mediated by CA³⁻- independent phospholipase A₂ but not cytosolic phospholipase A₁, which undergoes proteolytic inactivation," *Journal of Biological Chemistry*, vol. 273, no. 22, pp. 13870–13877, 1998.

[44] T. Smani, S. I. Zakharov, P. Csutora, E. Leno, E. S. Trepakova, and V. M. Bolotina, "A novel mechanism for the store-operated calcium influx pathway," *Nature Cell Biology*, vol. 6, no. 2, pp. 113–120, 2004.

[45] S. Bao, D. J. Miller, Z. Ma et al., "Male mice that do not express Group VIA Phospholipase A₂ produce spermatozoa with impaired motility and have greatly reduced fertility," *Journal of Biological Chemistry*, vol. 279, no. 37, pp. 38194–38200, 2004.

[46] S. Bao, H. Song, M. Wohltmann et al., "Insulin secretory responses and phospholipid composition of pancreatic islets from mice that do not express Group VIA phospholipase A₂ and effects of metabolic stress on glucose homeostasis," *Journal of Biological Chemistry*, vol. 281, no. 30, pp. 20958–20973, 2006.

[47] S. Bao, A. Bohrer, S. Ramanadham, W. Jin, S. Zhang, and J. Turk, "Effects of stable suppression of group VIA phospholipase A₂ expression on phospholipid content and composition, insulin secretion, and proliferation of INS-1 insulinoma cells," *Journal of Biological Chemistry*, vol. 281, no. 1, pp. 187–198, 2006.

[48] N. V. Morgan, S. K. Westaway, J. E. V. Morton et al., "PLA₂G₆, encoding a phospholipase A₂, is mutated in neurodegenerative disorders with high brain iron," *Nature Genetics*, vol. 38, no. 7, pp. 752–756, 2006.

[49] G. R. Kinsey, J. MChowat, C. S. Beckett, and R. G. Schnellmann, "Identification of calcium-independent phospholipase A₂ in mitochondria and its role in mitochondrial oxidative stress," *American Journal of Physiology*, vol. 292, no. 2, pp. F853–F860, 2007.

[50] D. J. Mancuso, C. M. Jenkins, H. F. Sims, J. M. Cohen, J. Yang, and R. W. Gross, "Complex transcriptional and translational regulation of iPLA₂ and resulting in multiple gene products containing dual competing sites for mitochondrial or peroxisomal localization," *European Journal of Biochemistry*, vol. 271, no. 23-24, pp. 4709–4724, 2004.

[51] M. Murakami, S. Masuda, K. Ueda-Semmyo et al., "Group VIA CA²⁺-independent phospholipase A₂ promotes cellular membrane hydrolysis and prostaglandin production in a manner distinct from other intracellular phospholipases A₂," *Journal of Biological Chemistry*, vol. 280, no. 14, pp. 14028–14041, 2005.

[52] H. Tanaka, R. Takeya, and H. Sumimoto, "A novel intracellular membrane-bound calcium-independent phospholipase A₂," *Biochemical and Biophysical Research Communications*, vol. 272, no. 2, pp. 320–326, 2000.

[53] J. Yang, X. Han, and R. W. Gross, "Identification of hepatic peroxisomal phospholipase A₂ and characterization of arachidonic acid-containing choline glycerophospholipids in hepatic peroxisomes," *FEBS Letters*, vol. 546, no. 2-3, pp. 247–250, 2003.

[54] W. Yan, C. M. Jenkins, X. Han et al., "The highly selective production of 2-arachidonoyl lysophosphatidylcholine catalyzed by purified calcium-independent phospholipase A₂: identification of a novel enzymatic mediator for the generation of a key branch point intermediate in eicosanoid signaling," *Journal of Biological Chemistry*, vol. 280, no. 29, pp. 26669–26679, 2005.

[55] M. J. Wolf, Y. Izumi, C. F. Zorumski, and R. W. Gross, "Long-term potentiation requires activation of calcium-independent phospholipase A₂," *FEBS Letters*, vol. 377, no. 3, pp. 358–362, 1995.

[56] H. C. Yang, M. Mossior, B. Ni, and E. A. Dennis, "Regional distribution, ontogeny, purification, and characterization of the CA³⁻-independent phospholipase A₂ from rat brain," *Journal of Neurochemistry*, vol. 73, no. 3, pp. 1278–1287, 1999.

[57] G. R. Kinsey, B. S. Cummings, C. S. Beckett et al., "Identification and distribution of endoplasmic reticulum iPLA₂," *Biochemical and Biophysical Research Communications*, vol. 327, no. 1, pp. 287–293, 2005.

[58] K. W. Underwood, C. Song, R. W. Kriz, X. J. Chang, J. L. Knopf, and L. L. Lin, "A novel calcium-independent phospholipase A₂, cPLA₂-y, that is prenylated and contains homology to cPLA₂," *Journal of Biological Chemistry*, vol. 273, no. 34, pp. 21926–21932, 1998.
[59] C. M. Jenkins, X. Han, D. J. Mancuso, and R. W. Gross, “Identification of calcium-independent phospholipase $A_2$ (iPLA$_2$) $\beta$ and not iPLA$_{2\gamma}$ as the mediator of arginine vasopressin-induced arachidonic acid release in A-10 smooth muscle cells. Enantioselective mechanism-based discrimination of mammalian iPLA$_2$s,” *Journal of Biological Chemistry*, vol. 277, no. 36, pp. 32807–32814, 2002.

[60] S. Fujita, Y. Ikegaya, M. Nishikawa, N. Nishiyama, and N. Matsuki, “Docosahexaenoic acid improves long-term potentiation attenuated by phospholipase $A_2$ inhibitor in rat hippocampal slices,” *British Journal of Pharmacology*, vol. 132, no. 7, pp. 1417–1422, 2001.

[61] X. H. Zhang and M. M. Poo, “Progress in neural plasticity,” *Science China Life Sciences*, vol. 53, no. 3, pp. 322–329, 2010.

[62] J. Xu, S. Yu, A. Y. Sun, and G. Y. Sun, “Oxidant-mediated AA release from astrocytes involves cPLA$_2$ and iPLA$_2$,” *Biochemistry*, vol. 43, no. 4, pp. 918–930, 2004.

[63] X. Xie, J. S. Liaw, M. Baudry, and T. W. Berger, “Novel expression mechanism for synaptic potentiation: alignment of presynaptic release site and postsynaptic receptor,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 94, no. 13, pp. 6983–6988, 1997.

[64] W. Y. Lu, H. Y. Man, W. Ju, W. S. Trimble, J. F. MacDonald, and Y. T. Wang, “Activation of synaptic NMDA receptors induces membrane insertion of new AMPA receptors and LTP in cultured hippocampal neurons,” *Neuron*, vol. 29, no. 1, pp. 243–254, 2001.

[65] L. Pickard, J. Noël, J. K. Duckworth et al., “Transient synaptic activation of NMDA receptors leads to the insertion of native AMPA receptors at hippocampal neuronal plasma membranes,” *Neuropharmacology*, vol. 41, no. 6, pp. 700–713, 2001.

[66] M. A. Martel, C. Patenaude, C. Ménard, S. Alaux, B. S. Cummings, and G. Massicotte, “A novel role for calcium-independent phospholipase $A_2$ in $\alpha$-amino-3-hydroxy-5-methylisoxazole-propionate receptor regulation during long-term potentiation,” *European Journal of Neuroscience*, vol. 23, no. 2, pp. 503–513, 2006.

[67] C. Péchoux, R. Boisgard, E. Chanat, and F. Lavialle, “Ca$^{2+}$-independent phospholipase $A_2$ participates in the vesicular transport of milk proteins,” *Biochimica et Biophysica Acta*, vol. 1743, no. 3, pp. 317–329, 2005.

[68] G. Broutman and M. Baudry, “Involvement of the secretory pathway for AMPA receptors in NMDA-induced potentiation in hippocampus,” *Journal of Neuroscience*, vol. 21, no. 1, pp. 27–34, 2001.

[69] C. Holscher and S. P. R. Rose, “Inhibitors of phospholipase $A_2$ produce amnesia for a passive avoidance task in the chick,” *Behavioral and Neural Biology*, vol. 61, no. 3, pp. 225–232, 1994.

[70] C. Holscher, L. Caneviari, and G. Richter-Levin, “Inhibitors of PLA$_2$ and NO synthase cooperate in producing amnesia of a spatial task,” *NeuroReport*, vol. 6, no. 5, pp. 730–732, 1995.

[71] R. Pérez, R. Melero, M. A. Balboa, and J. Balsinde, “Role of group VIA calcium-independent phospholipase $A_2$ activity in rat hippocampus impair acquisition of short- and long-term memory,” *Psychopharmacology*, vol. 181, no. 2, pp. 392–400, 2005.

[72] J. Ambros-Ingersen and G. Lynch, “Channel gating kinetics and synaptic efficacy: a hypothesis for expression of long-term potentiation,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 90, no. 16, pp. 7903–7907, 1993.

[73] J. Ambros-Ingersen, P. Xiao, J. Larson, and G. Lynch, “Waveform analysis suggests that LTP alters the kinetics of synaptic receptor channels,” *Brain Research*, vol. 620, no. 2, pp. 237–244, 1993.

[74] X. Xie, J. S. Liaw, M. Baudry, and T. W. Berger, “Novel expression mechanism for synaptic potentiation: alignment of presynaptic release site and postsynaptic receptor,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 94, no. 13, pp. 6983–6988, 1997.
phospholipase $A_2$ in oxidant-induced renal cell death,” *American Journal of Physiology*, vol. 283, no. 3, pp. F492–F498, 2002.

[89] B. Peterson, T. Knotts, and B. S. Cummings, “Involvement of CA$^{2+}$-independent phospholipase $A_2$ isoforms in oxidant-induced neural cell death,” *NeuroToxicology*, vol. 28, no. 1, pp. 150–160, 2007.

[90] M. Strokin, O. Chechneva, K. G. Reymann, and G. Reiser, “Neuroprotection of rat hippocampal slices exposed to oxygen-glucose deprivation by enrichment with docosahexaenoic acid and by inhibition of hydrolysis of docosahexaenoic acid-containing phospholipids by calcium independent phospholipase $A_2$,” *Neuroscience*, vol. 140, no. 2, pp. 547–553, 2006.

[91] O. V. Forlenza, C. T. Mendes, S. K. N. Marie, and W. F. Gattaz, “Inhibition of phospholipase $A_2$ reduces neurite outgrowth and neuronal viability,” *Prostaglandins Leukotrienes and Essential Fatty Acids*, vol. 76, no. 1, pp. 47–55, 2007.

[92] C. T. Mendes, W. F. Gattaz, E. L. Schaefter, and O. V. Forlenza, “Modulation of phospholipase $A_2$ activity in primary cultures of rat cortical neurons,” *Journal of Neural Transmission*, vol. 112, no. 10, pp. 1297–1308, 2005.

[93] I. Malik, J. Turk, D. J. Mancuso et al., “Disrupted membrane homeostasis and accumulation of ubiquitinated proteins in a mouse model of infantile neuroaxonal dystrophy caused by PLA$_2$G6 mutations,” *American Journal of Pathology*, vol. 172, no. 2, pp. 406–416, 2008.

[94] K. Shizawa, H. Sumi, M. Ikawa et al., “Neuroaxonal dystrophy caused by group VIA phospholipase $A_2$ deficiency in mice: a model of human neurodegenerative disease,” *Journal of Neuroscience*, vol. 28, no. 9, pp. 2212–2220, 2008.

[95] G. R. Kinsey, J. Mchowat, K. S. Patrick, and R. G. Schnellmann, “Role of CA$^{2+}$-independent phospholipase $A_2$ in CA$^{2+}$-induced mitochondrial permeability transition,” *Journal of Pharmacology and Experimental Therapeutics*, vol. 321, no. 2, pp. 707–715, 2007.

[96] D. Cohen, J. Papillon, L. Aoudjit, H. Li, A. V. Cybulsky, and T. Takano, “Role of calcium-independent phospholipase $A_2$ in complement-activated glomerular epithelial cell injury,” *American Journal of Physiology*, vol. 294, no. 3, pp. F469–F479, 2008.

[97] C. Menard, C. Chartier, C. Patenaude et al., “Calcium-independent phospholipase $A_2$ influences AMPA-mediated toxicity of hippocampal slices by regulating the GluR1 subunit in synaptic membranes,” *Hippocampus*, vol. 17, no. 11, pp. 1109–1120, 2007.

[98] C. Villmann and C. M. Becker, “Reviews: on the hypes and falls in neuroprotection: targeting the NMDA receptor,” *Neuroscientist*, vol. 13, no. 6, pp. 594–613, 2007.

[99] S. Kwak and J. H. Weiss, “Calcium-permeable AMPA channels in neurodegenerative disease and ischemia,” *Current Opinion in Neurobiology*, vol. 16, no. 3, pp. 281–287, 2006.

[100] C. Menard, C. Patenaude, and G. Massicotte, “Phosphorylation of AMPA receptor subunits is differentially regulated by phospholipase $A_2$ inhibitors,” *Neuroscience Letters*, vol. 389, no. 1, pp. 51–56, 2005.

[101] B. Sommer, M. Köhler, R. Sprengel, and P. H. Seeburg, “RNA editing in brain controls a determinant of ion flow through glutamate-gated channels,” *Cell*, vol. 67, no. 1, pp. 11–19, 1991.

[102] J. R. P. Geiger, T. Melcher, D. S. Koh et al., “Relative abundance of subunit mRNAs determines gating and CA$^{2+}$ permeability of AMPA receptors in principal neurons and interneurons in rat CNS,” *Neuron*, vol. 15, no. 1, pp. 193–204, 1995.

[103] T. C. Thiagarajan, M. Lindskog, and R. W. Tsien, “Adaptation to synaptic inactivity in hippocampal neurons,” *Neuron*, vol. 47, no. 5, pp. 725–737, 2005.

[104] D. Stellwagen, E. C. Beattie, J. Y. Seo, and R. C. Malenka, “Differential regulation of AMPA receptor and GABA receptor trafficking by tumor necrosis factor-α,” *Journal of Neuroscience*, vol. 25, no. 12, pp. 3219–3228, 2005.

[105] J. T. Green, S. K. Orr, and R. P. Bazinet, “The emerging role of group V calcium-independent phospholipase $A_2$ in releasing docosahexaenoic acid from brain phospholipids,” *Journal of Lipid Research*, vol. 49, no. 5, pp. 939–944, 2008.

[106] M. Strokin, M. Sergeeva, and G. Reiser, “Docosahexaenoic acid and arachidonic acid release in rat brain astrocytes is mediated by two separate isoforms of phospholipase $A_2$ and is differently regulated by cyclic AMP and CA$^{2+}$,” *British Journal of Pharmacology*, vol. 139, no. 5, pp. 1014–1022, 2003.

[107] M. Strokin, M. Sergeeva, and G. Reiser, “Prostaglandin synthesis in rat brain astrocytes is under the control of the n-3 docosahexaenoic acid, released by group VIA calcium-independent phospholipase $A_2$,” *Journal of Neurochemistry*, vol. 102, no. 6, pp. 1771–1782, 2007.

[108] J. A. Glomset, “Role of docosahexaenoic acid in neuronal plasma membranes,” *Science’s STKE*, vol. 2006, no. 321, p. pe6, 2006.

[109] K. A. Youdim, A. Martin, and J. A. Joseph, “Essential fatty acids and the brain: possible health implications,” *International Journal of Developmental Neuroscience*, vol. 18, no. 4-5, pp. 383–399, 2000.

[110] J. Catalan, T. Morishugi, B. Slotnick, M. Murthy, R. S. Greiner, and N. Salem, “Cognitive deficits in docosahexaenoic acid-deficient rats,” *Behavioral Neuroscience*, vol. 116, no. 6, pp. 1022–1031, 2002.

[111] I. Fedorova and N. Salem Jr., “Omega-3 fatty acids and rodent behavior,” *Prostaglandins Leukotrienes and Essential Fatty Acids*, vol. 75, no. 4-5, pp. 271–289, 2006.

[112] T. Takeuchi, Y. Fukushima, and E. Harada, “Influence of a dietary n-3 fatty acid deficiency on the cerebral cholineal contents, EEG and learning ability in rat,” *Behavioural Brain Research*, vol. 131, no. 1-2, pp. 193–203, 2002.

[113] F. Calon and G. Cole, “Neuroprotective action of omega-3 polyunsaturated fatty acids against neurodegenerative diseases: evidence from animal studies,” *Prostaglandins Leukotrienes and Essential Fatty Acids*, vol. 77, no. 5-6, pp. 287–293, 2007.

[114] F. Calon, G. P. Lim, T. Morihara et al., “Dietary n-3 polyunsaturated fatty acid depletion activates caspases and decreases NMDA receptors in the brain of a transgenic mouse model of Alzheimer’s disease,” *European Journal of Neuroscience*, vol. 22, no. 3, pp. 617–626, 2005.

[115] F. Calon, G. P. Lim, F. Yang et al., “Docosahexaenoic acid protects from dendritic pathology in an Alzheimer’s disease mouse model,” *Neuron*, vol. 43, no. 3, pp. 633–645, 2004.

[116] M. Bousquet, M. Saint-Pierre, C. Julien, N. Salem, F. Cicchetti, and F. Calon, “Beneficial effects of dietary omega-3 polyunsaturated fatty acid on toxin-induced neuronal degeneration in an animal model of Parkinson’s disease,” *FASEB Journal*, vol. 22, no. 4, pp. 1213–1225, 2008.

[117] C. Julien, C. Tremblay, A. Phivilay et al., “High-fat diet aggravates amyloid-beta and tau pathologies in the 3xTg-AD mouse model,” *Neurobiology of Aging*, vol. 31, no. 9, pp. 1516–1531, 2010.
K. N. Green, H. Martinez-Coria, H. Khashwji et al., "Dietary omega-3 fatty acids normalize BDNF levels, reduce oxidative damage, and counteract learning disability after traumatic brain injury in rats," *Journal of Neurotrauma*, vol. 21, no. 10, pp. 1457–1467, 2004.

X. Wang, X. Zhao, Z. Y. Mao, X. M. Wang, and Z. L. Liu, "Neuroprotective effect of docosahexaenoic acid on glutamate-induced cytotoxicity in rat hippocampal cultures," *Neuroreport*, vol. 14, no. 18, pp. 2457–2461, 2003.

C. Ménard, C. Patenaude, A.-M. Gagné, and G. Massicotte, "AMPA receptor-mediated cell death is reduced by docosahexaenoic acid but not by eicosapentaenoic acid in area CA1 of hippocampal slice cultures," *Journal of Neuroscience Research*, vol. 87, no. 4, pp. 876–886, 2009.

K. N. Green, H. Martínez-Coria, H. Khashwji et al., "Dietary docosahexaenoic acid and docosapentaenoic acid ameliorate amyloid-β and tau pathology via a mechanism involving presenilin 1 levels," *Journal of Neuroscience*, vol. 27, no. 16, pp. 4385–4395, 2007.

M. Oksman, H. Ivonen, E. Hogyes et al., "Impact of different saturated fatty acid, polyunsaturated fatty acid and cholesterol containing diets on beta-amyloid accumulation in APP/PS1 transgenic mice," *Neurobiology of Disease*, vol. 23, no. 3, pp. 563–572, 2006.

M. D. Weingarten, A. H. Lockwood, S. Y. Hwo, and M. W. Kirschen, "A protein factor essential for microtubule assembly," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 72, no. 5, pp. 1858–1862, 1975.

D. W. Cleveland, S. Y. Hwo, and M. W. Kirschen, "Physical and chemical properties of purified tau factor and the role of tau in microtubule assembly," *Journal of Molecular Biology*, vol. 116, no. 2, pp. 227–247, 1977.

N. Shahani and R. Brandt, "Functions and malfunctions of the tau proteins," *Cellular and Molecular Life Sciences*, vol. 59, no. 10, pp. 1668–1680, 2002.

P. S. Yamauchi and D. L. Purich, "Microtubule-associated protein interactions with actin filaments: evidence for differential behavior of neuronal MAP-2 and tau in the presence of phosphatidylinositol-3-phosphate," *Biochemical and Biophysical Research Communications*, vol. 190, no. 3, pp. 710–715, 1993.

S. C. Selden and T. D. Pollard, "Phosphorylation of microtubule-associated proteins regulates their interaction with actin filaments," *Journal of Biological Chemistry*, vol. 258, no. 11, pp. 7064–7071, 1983.

R. Brandt, J. Léger, and G. Lee, "Interaction of tau with the neural plasma membrane mediated by tau's amino-terminal projection domain," *Journal of Cell Biology*, vol. 131, no. 5, pp. 1327–1340, 1995.

T. Maas, J. Eidenmüller, and R. Brandt, "Interaction of tau with the neural membrane cortex is regulated by phosphorylation at sites that are modified in paired helical filaments," *Journal of Biological Chemistry*, vol. 275, no. 21, pp. 15733–15740, 2000.

S. M. Jenkins and G. V. W. Johnson, "Tau complexes with phospholipase C-γ in situ," *NeuroReport*, vol. 9, no. 1, pp. 67–71, 1998.

G. Lee, S. Todd Newman, D. L. Gard, H. Band, and G. Panchamoorthy, "Tau interacts with src-family non-receptor tyrosine kinases," *Journal of Cell Science*, vol. 111, no. 21, pp. 3167–3177, 1998.

H. Liao, Y. Li, D. L. Brautigan, and G. G. Gundersen, "Protein phosphatase 1 is targeted to microtubules by the microtubule- associated protein tau," *Journal of Biological Chemistry*, vol. 273, no. 34, pp. 21901–21908, 1998.

E. Sontag, V. Nunbhakdi-Craig, G. Lee, G. S. Bloom, and M. C. Mumby, "Regulation of the phosphorylation state and microtubule-binding activity of tau by protein phosphatase 2A," *Neuron*, vol. 17, no. 6, pp. 1201–1207, 1996.

A. Agarwal-Mawal, H. Y. Qureshi, P. W. Cafferty et al., "14-3-3 Connects glycogen synthase kinase-3β to tau within a brain microtubule-associated tau phosphorylation complex," *Journal of Biological Chemistry*, vol. 278, no. 15, pp. 12722–12728, 2003.

C. H. Reynolds, C. J. Garwood, S. Wray et al., "Phosphorylation regulates tau interactions with Src homology 3 domains of phosphatidylinositol 3-kinase, phosphatidylinositol 3,4,5-triphosphate, and Src family kinases," *Journal of Biological Chemistry*, vol. 283, no. 26, pp. 18177–18186, 2008.

I. E. Vega, E. E. Traverso, Y. Ferrer-Acosta et al., "A novel calcium-binding protein is associated with tau proteins in tauopathy," *Journal of Neurochemistry*, vol. 106, no. 1, pp. 96–106, 2008.

Y. Zhang, Q. Tian, Q. Zhang, X. Zhou, S. Liu, and J. Z. Wang, "Hyperphosphorylation of microtubule-associated tau protein plays dual role in neurodegeneration and neuroprotection," *Pathophysiology*, vol. 16, no. 4, pp. 311–316, 2009.

M. A. Burack and S. Halpain, "Site-specific regulation of Alzheimer-like tau phosphorylation in living neurons," *Neuroscience*, vol. 72, no. 1, pp. 167–184, 1996.

T. F. Gendron and L. Petrucelli, "The role of tau in neurodegeneration," *Molecular Neurodegeneration*, vol. 4, p. 13, 2009.

C. A. Maurage, N. Sergeant, M. M. Ruchoux, J. J. Hauw, and A. Delacourte, "Phosphorylated serine 199 of microtubule-associated protein tau is a neuronal epitope abundantly expressed in youth and an early marker of tau pathology," *Acta Neuropathologica*, vol. 105, no. 2, pp. 89–97, 2003.

X. Bi, T. S. Haque, J. Zhou et al., "Novel cathepsin D inhibitors block the formation of hyperphosphorylated tau fragments in hippocampus," *Journal of Neurochemistry*, vol. 74, no. 4, pp. 1469–1477, 2000.

X. Bi, A. P. Yong, J. Zhou, C. E. Ribak, and G. Lynch, "Rapid induction of intraneuronal neurofibrillary tangles in..."
Neural Plasticity

apolipoprotein E-deficient mice,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 98, no. 15, pp. 8832–8837, 2001.

[148] V. J. De-Paula, E. L. Schaeffer, L. L. Talib, W. F. Gattaz, and O. V. Forlenza, “Inhibition of phospholipase A2 increases Tau phosphorylation at Ser214 in embryonic rat hippocampal neurons,” *Prostaglandins Leukotrienes and Essential Fatty Acids*, vol. 82, no. 1, pp. 57–60, 2010.

[149] E. L. Schaeffer, V. J. De-Paula, E. R. Da Silva et al., “Inhibition of phospholipase A2 in rat brain decreases the levels of total Tau protein,” *Journal of Neural Transmission*, vol. 118, no. 9, pp. 1273–1279, 2011.

[150] R. López-Vales, N. Ghasemlou, A. Redensek et al., “Phospholipase A2 superfamily members play divergent roles after spinal cord injury,” *FASEB Journal*, vol. 25, no. 12, pp. 4240–4252, 2011.

[151] J. J. Palop, J. Chin, and L. Mucke, “A network dysfunction perspective on neurodegenerative diseases,” *Nature*, vol. 443, no. 7113, pp. 768–773, 2006.

[152] R. O. Sanchez-Mejia, J. W. Newman, S. Toh et al., “Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer’s disease,” *Nature Neuroscience*, vol. 11, no. 11, pp. 1311–1318, 2008.

[153] K. Seleznev, C. Zhao, X. H. Zhang, K. Song, and Z. A. Ma, “Calcium-independent phospholipase A2 localizes in and protects mitochondria during apoptotic induction by staurosporine,” *Journal of Biological Chemistry*, vol. 281, no. 31, pp. 22275–22288, 2006.

[154] G. R. Kinsey, J. L. Blum, M. D. Covington, B. S. Cummings, J. McHowat, and R. G. Schnellmann, “Decreased iPLA2γ expression induces lipid peroxidation and cell death and sensitizes cells to oxidant-induced apoptosis,” *Journal of Lipid Research*, vol. 49, no. 7, pp. 1477–1487, 2008.

[155] C. A. Hansson Petersen, N. Alikhani, H. Behbahani et al., “The amyloid β-peptide is imported into mitochondria via the TOM import machinery and localized to mitochondrial cristae,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 105, no. 35, pp. 13145–13150, 2008.

[156] S. Smesny, D. Kinder, I. Willhardt et al., “Increased calcium-independent phospholipase A2 activity in first but not in multiepisode chronic schizophrenia,” *Biological Psychiatry*, vol. 57, no. 4, pp. 399–405, 2005.

[157] L. M. Wiedholz, W. A. Owens, R. E. Horton et al., “Mice lacking the AMPA GluR1 receptor exhibit striatal hyperdopaminergia and 'schizophrenia-related' behaviors,” *Molecular Psychiatry*, vol. 13, no. 6, pp. 631–640, 2008.

[158] L. Y. Lee, W. Y. Ong, A. A. Farooqui, and J. M. Burgunder, “Role of calcium-independent phospholipase A2 in cortex striatum thalamus cortex circuitry-enzyme inhibition causes vacuous chewing movements in rats,” *Psychopharmacology*, vol. 195, no. 3, pp. 387–395, 2007.

[159] D. J. Mancuso, P. Kotzbauer, D. F. Wozniak et al., “Genetic ablation of calcium-independent phospholipase A2γ leads to alterations in hippocampal cardiolipin content and molecular species distribution, mitochondrial degeneration, autophagy, and cognitive dysfunction,” *Journal of Biological Chemistry*, vol. 284, no. 51, pp. 35632–35644, 2009.

[160] D. J. Mancuso, H. F. Sims, X. Han et al., “Genetic ablation of calcium-independent phospholipase A2γ leads to alterations in mitochondrial lipid metabolism and function resulting in a deficient mitochondrial bioenergetic phenotype,” *Journal of Biological Chemistry*, vol. 282, no. 48, pp. 34611–34622, 2007.

[161] E. L. Schaeffer, O. V. Forlenza, and W. F. Gattaz, “Phospholipase A2 activation as a therapeutic approach for cognitive enhancement in early-stage Alzheimer disease,” *Psychopharmacology*, vol. 202, no. 1–3, pp. 37–51, 2009.